Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.

Literature DB >> 22814295

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.

A Fasan, C Eder, C Haferlach, V Grossmann, A Kohlmann, F Dicker, W Kern, T Haferlach, S Schnittger.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2012 PMID： 22814295 DOI： 10.1038/leu.2012.174

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

39 in total

1. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.

Authors: Xinan Wang; Hideki Muramatsu; Yusuke Okuno; Hirotoshi Sakaguchi; Kenichi Yoshida; Nozomu Kawashima; Yinyan Xu; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Shoji Saito; Yozo Nakazawa; Taro Masunari; Tadashi Hirose; Shaimaa Elmahdi; Atsushi Narita; Sayoko Doisaki; Olfat Ismael; Hideki Makishima; Asahito Hama; Satoru Miyano; Yoshiyuki Takahashi; Seishi Ogawa; Seiji Kojima
Journal: Haematologica Date: 2015-05-28 Impact factor: 9.941

Review 2. The GATA factor revolution in hematology.

Authors: Koichi R Katsumura; Emery H Bresnick
Journal: Blood Date: 2017-02-08 Impact factor: 22.113

3. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Authors: F Theis; A Corbacioglu; V I Gaidzik; P Paschka; D Weber; L Bullinger; M Heuser; A Ganser; F Thol; B Schlegelberger; G Göhring; C-H Köhne; U Germing; P Brossart; H-A Horst; D Haase; K Götze; M Ringhoffer; W Fiedler; D Nachbaur; T Kindler; G Held; M Lübbert; M Wattad; H R Salih; J Krauter; H Döhner; R F Schlenk; K Döhner
Journal: Leukemia Date: 2016-07-04 Impact factor: 11.528

4. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.

Authors: Fei Yang; Tauangtham Anekpuritanang; Richard D Press
Journal: Mol Diagn Ther Date: 2020-02 Impact factor: 4.074

5. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.

Authors: Xiang-Mei Wen; Jiang Lin; Jing Yang; Dong-Ming Yao; Zhao-Qun Deng; Chun-Yan Tang; Gao-Fei Xiao; Lei Yang; Ji-Chun Ma; Jia-Bo Hu; Wei Qian; Jun Qian
Journal: Int J Clin Exp Pathol Date: 2014-09-15

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.

1. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.

Review 2. The GATA factor revolution in hematology.

3. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

4. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.

5. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.

6. The role of different genetic subtypes of CEBPA mutated AML.

7. Can somatic GATA2 mutation mimic germ line GATA2 mutation?

Review 8. New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing.

Review 9. Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Review 10. The use of molecular genetics to refine prognosis in acute myeloid leukemia.